CL2012000042A1 - Compuestos derivados de imidazo[1,2-a]pirazin-7-il; composición farmacéutica que comprende a uno de los compuestos; y uso de uno de los compuestos en la preparación de un medicamento útil para tratar una enfermedad relacionada con el género plasmodium en un sujeto. - Google Patents

Compuestos derivados de imidazo[1,2-a]pirazin-7-il; composición farmacéutica que comprende a uno de los compuestos; y uso de uno de los compuestos en la preparación de un medicamento útil para tratar una enfermedad relacionada con el género plasmodium en un sujeto.

Info

Publication number
CL2012000042A1
CL2012000042A1 CL2012000042A CL2012000042A CL2012000042A1 CL 2012000042 A1 CL2012000042 A1 CL 2012000042A1 CL 2012000042 A CL2012000042 A CL 2012000042A CL 2012000042 A CL2012000042 A CL 2012000042A CL 2012000042 A1 CL2012000042 A1 CL 2012000042A1
Authority
CL
Chile
Prior art keywords
compounds
alkylocl
alkyl
hydrogen
imidazo
Prior art date
Application number
CL2012000042A
Other languages
English (en)
Inventor
K Chatterjee Arnab
Nagle Advait
Wu Tao
Tully David
L Kuhen Kelli
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42727573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000042(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2012000042A1 publication Critical patent/CL2012000042A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/022—Boron compounds without C-boron linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPUESTOS DERIVADOS DE IMIDAZO[1 ,2-AJPIRAZIN-7-II REPRESENTADO POR LA FORMULA LA: EN DONDE RA SE SELECCIONA A PARTIR DE -X3NR7R8, -X30R8, -X35(0)0-2R8, -X3C(0)NR7R8 Y BENCILO OPCIONA!MENTE SUSTITUIDO COMO SE DESCRIBE EN LAS REIVINDICACIONES; R2 SE SELECCIONA ENTRE HIDRÓGENO, ALQUILOCL-6, AMINO, CICLOALQUILC3-8-ALQUILOCO-4, ARIL-C6-10-ALQUILOCO-4, ALQUILOCL -6 HALO-SUSTITUIDO, ALQUILOCL -6 HIDROXI-SUSTITUIDO Y HETEROCICLIL-ALQUILOCO-4; DEFINIDO EN LAS REIVINDICACIONES; EN DONDE DICHO ARILOC6-1 O O HETEROCICLO DE R2 ESTÁ OPCIONALMENTE SUSTITUIDO; O R2 Y R3 JUNTO CON EL ÁTOMO DE CARBONO AL CUAL R2 Y R3 ESTÁN UNIDOS FORMAN UN CICLOALQUILOC3-8; O R2 Y R13 JUNTO CON LOS ÁTOMOS A LOS CUALES P2 Y R13 ESTÁN UNIDOS FORMAN UN ANILLO HETEROCÍCLICO MONO O FUSIONADO COMO SE DEFINE EN LAS REIVINDICACIONES; R4 Y R5 SE SELECCIONA ENTRE HIDRÓGENO Y ALQUILOCL-6; O P4 Y RS JUNTO CON EL ÁTOMO DE CARBONO AL CUAL R4 Y P5 ESTÁN UNIDOS FORMAN UN CICLOALQUILOC3-8; P6 SE SELECCIONA ENTRE ARILOC6-10, CICLOALQUILOC3-8 Y UN ANILLO HETEROCÍCLICO MONO O FUSIONADO DEFINIDO EN LAS REIVINDICACIONES; R9, RIO, Y RL 1, SE SELECCIONA ENTRE HIDRÓGENO Y ALQUILO CI-6; R12 SE SELECCIONA ENTRE HIDRÓGENO Y ALQUILO C1-6; O RL 1 Y R12 COMBINADOS PARA FORMAR UN C(0); O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO, EL RESTO DE LOS RADICALES SE DEFINEN COMO EN EL CAPÍTULO REIVINDICATORIO. ADICIONALMENTE, LA INVENCIÓN RECLAMA COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN DICHOS COMPUESTOS Y USOS PARA TRATAR O PREVENIR EL PALUDISMO.
CL2012000042A 2009-07-09 2012-01-06 Compuestos derivados de imidazo[1,2-a]pirazin-7-il; composición farmacéutica que comprende a uno de los compuestos; y uso de uno de los compuestos en la preparación de un medicamento útil para tratar una enfermedad relacionada con el género plasmodium en un sujeto. CL2012000042A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22443309P 2009-07-09 2009-07-09

Publications (1)

Publication Number Publication Date
CL2012000042A1 true CL2012000042A1 (es) 2012-12-21

Family

ID=42727573

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000042A CL2012000042A1 (es) 2009-07-09 2012-01-06 Compuestos derivados de imidazo[1,2-a]pirazin-7-il; composición farmacéutica que comprende a uno de los compuestos; y uso de uno de los compuestos en la preparación de un medicamento útil para tratar una enfermedad relacionada con el género plasmodium en un sujeto.

Country Status (38)

Country Link
US (3) US8557801B2 (es)
EP (2) EP2737927B1 (es)
JP (1) JP5432376B2 (es)
KR (1) KR101378666B1 (es)
CN (1) CN102471341B (es)
AR (1) AR077463A1 (es)
AU (1) AU2010271247B2 (es)
BR (1) BR112012000413B1 (es)
CA (1) CA2767664C (es)
CL (1) CL2012000042A1 (es)
CO (1) CO6491060A2 (es)
CR (1) CR20120008A (es)
CU (1) CU24155B1 (es)
DK (1) DK2451814T3 (es)
EA (1) EA019655B1 (es)
EC (1) ECSP12011585A (es)
ES (2) ES2477940T3 (es)
GT (1) GT201200004A (es)
HK (1) HK1164304A1 (es)
HN (1) HN2012000023A (es)
HR (1) HRP20140641T1 (es)
IL (1) IL217384A (es)
JO (1) JO3156B1 (es)
MA (1) MA33419B1 (es)
MX (1) MX2012000389A (es)
MY (1) MY157238A (es)
NZ (1) NZ597275A (es)
PE (1) PE20130399A1 (es)
PL (1) PL2451814T3 (es)
PT (1) PT2451814E (es)
SG (1) SG176938A1 (es)
SI (1) SI2451814T1 (es)
SM (1) SMT201400096B (es)
TN (1) TN2011000647A1 (es)
TW (1) TWI421252B (es)
UA (1) UA103930C2 (es)
UY (1) UY32776A (es)
WO (1) WO2011006143A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2884767A1 (en) 2012-11-14 2014-05-22 Stephan Bachmann Imidazopyridine derivatives
ME03042B (me) * 2012-11-19 2018-10-20 Novartis Ag Jedinjenja i kompozicije za tretman parazitskih oboljenja
US20150291598A1 (en) * 2012-11-19 2015-10-15 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US8871754B2 (en) 2012-11-19 2014-10-28 Irm Llc Compounds and compositions for the treatment of parasitic diseases
CN103126782B (zh) * 2013-02-26 2016-06-29 内蒙古农牧业科学院 一种寄生病的治疗方法
CN106029666B (zh) * 2013-12-19 2018-05-18 诺华股份有限公司 作为原生动物蛋白酶体抑制剂用于治疗寄生虫疾病例如利什曼病的[1,2,4]三唑并[1,5-a]嘧啶衍生物
US10526325B2 (en) 2015-07-31 2020-01-07 Merck Patent Gmbh Bicyclic heterocyclic derivatives
BR112019003158B1 (pt) * 2016-08-15 2022-10-25 Bayer Cropscience Aktiengesellschaft Derivados de heterociclo bicíclico condensado, seu uso, formulação agroquímica, e método para controlar pragas animais
WO2018198021A1 (en) * 2017-04-24 2018-11-01 Novartis Ag Therapeutic regimen of 2-amino-l-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8h)-yl)ethanone and combinations thereof
LT3652178T (lt) 2017-07-14 2024-04-10 F. Hoffmann-La Roche Ag Bicikliniai ketoniniai junginiai ir jų naudojimo būdai
JP2020536853A (ja) * 2017-10-04 2020-12-17 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 転写因子ｓａｌｌ４の小分子阻害およびその使用
WO2022049548A1 (en) 2020-09-04 2022-03-10 Novartis Ag Kaf156 combinations and methods for the treatment of malaria
WO2023168107A2 (en) * 2022-03-04 2023-09-07 University Of Central Florida Research Foundation, Inc. Compounds and compositions for anitmalarial therapeutic and prophylactic use
CN114569711B (zh) * 2022-03-24 2024-04-19 安徽医科大学 一种预防弓形虫病的ME49Δcdpk3减毒活疫苗及其制备方法和应用
WO2024006970A2 (en) * 2022-07-01 2024-01-04 The Scripps Research Institute Antimalarial compounds
WO2024006974A2 (en) * 2022-07-01 2024-01-04 The Scripps Research Institute Antimalarial compounds
WO2024006971A2 (en) * 2022-07-01 2024-01-04 The Scripps Research Institute Antimalarial compounds

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK476885D0 (da) 1985-10-17 1985-10-17 Ferrosan As Heterocycliske forbindelser og fremgangsmaader til fremstilling heraf
US6673927B2 (en) 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
RU2263111C2 (ru) 1998-06-12 2005-10-27 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик Сас Имидазольные производные
FR2780974B1 (fr) 1998-07-08 2001-09-28 Sod Conseils Rech Applic Utilisation de derives d'imidazopyrazines pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimetrique
ES2328564T3 (es) * 1998-12-31 2009-11-16 Ipsen Pharma Inhibidores de la prenil transferasa.
CZ20021550A3 (cs) 1999-11-09 2003-02-12 Societe De Conseils De Recherches Et D'application Produkt zahrnující inhibitor transdukce signálů heterotrimerického G proteinu kombinovaný s jiným protirakovinným činidlem pro terapeutické použití v léčbě rakoviny
FR2803525B1 (fr) 2000-01-06 2002-05-03 Sod Conseils Rech Applic Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle
ATE360620T1 (de) 2000-08-01 2007-05-15 Sod Conseils Rech Applic Imidazolderivate
WO2002053558A1 (en) * 2001-01-02 2002-07-11 F.Hoffman-La Roche Ag Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists
FR2825278A1 (fr) 2001-05-30 2002-12-06 Sod Conseils Rech Applic Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US7307164B2 (en) 2002-03-25 2007-12-11 Merck & Co., Inc. β-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004028541A2 (en) 2002-09-27 2004-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Composition for the treatment of nasopharyngeal carcinoma and use thereof
AU2003297431A1 (en) 2002-12-20 2004-07-22 Pharmacia Corporation Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
EP1583534A4 (en) * 2002-12-20 2007-08-29 Merck & Co Inc 3-AMINO-4-PHENYLBUTANIC ACID DERIVATIVES AS DIPEPTIDYL-PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
CA2517427C (en) * 2003-03-06 2012-07-24 Merck & Co., Inc. Antiprotozoal imidazopyridine compounds
TW200505902A (en) * 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
ATE447574T1 (de) 2003-05-14 2009-11-15 Merck & Co Inc 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
FR2856688B1 (fr) 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
FR2867778B1 (fr) * 2004-03-16 2006-06-09 Sanofi Synthelabo Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme
BRPI0614732A2 (pt) 2005-08-11 2011-04-12 Hoffmann La Roche composição farmacêutica que compreende um inibidor de dpp-iv, uso de um inibidor de dpp-iv e método para o tratamento de enfermidades associadas com nìveis de glicose sanguìnea elevados
RU2318818C1 (ru) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
CN101495113A (zh) 2006-04-21 2009-07-29 史密丝克莱恩比彻姆公司 Il-8受体拮抗剂
WO2008006085A2 (en) 2006-07-07 2008-01-10 University Of Washington Compositions and methods for predicting inhibitors of protein targets
TW200808056A (en) * 2006-07-26 2008-02-01 Compal Communications Inc Rear projection display system
EA200900983A1 (ru) 2007-01-26 2010-02-26 Айрм Ллк Соединения и композиции в качестве ингибиторов киназы
US20080242862A1 (en) * 2007-03-27 2008-10-02 Calderwood David J Novel imidazo based heterocycles
EP2170337A4 (en) 2007-06-28 2013-12-18 Abbvie Inc NEW TRIAZOLOPYRIDAZINE
CN101357922B (zh) 2007-08-02 2011-05-18 山东轩竹医药科技有限公司 新的dpp-iv抑制剂
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
WO2009155388A1 (en) 2008-06-20 2009-12-23 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors

Also Published As

Publication number Publication date
CR20120008A (es) 2012-03-12
ES2477940T3 (es) 2014-07-18
GT201200004A (es) 2014-03-27
TW201105675A (en) 2011-02-16
CU24155B1 (es) 2016-03-31
US9963454B2 (en) 2018-05-08
AU2010271247A1 (en) 2012-01-19
NZ597275A (en) 2013-05-31
JP5432376B2 (ja) 2014-03-05
IL217384A (en) 2015-07-30
EP2451814B1 (en) 2014-04-09
EA019655B1 (ru) 2014-05-30
UA103930C2 (ru) 2013-12-10
US20110059934A1 (en) 2011-03-10
KR20120047939A (ko) 2012-05-14
CN102471341B (zh) 2014-07-02
KR101378666B1 (ko) 2014-03-26
MA33419B1 (fr) 2012-07-03
HRP20140641T1 (hr) 2014-09-26
IL217384A0 (en) 2012-02-29
CO6491060A2 (es) 2012-07-31
PL2451814T3 (pl) 2014-09-30
AR077463A1 (es) 2011-08-31
EP2451814A2 (en) 2012-05-16
SMT201400096B (it) 2014-09-08
TN2011000647A1 (en) 2013-05-24
SG176938A1 (en) 2012-01-30
HN2012000023A (es) 2014-08-18
EP2737927B1 (en) 2016-03-30
ECSP12011585A (es) 2012-02-29
CA2767664C (en) 2013-12-10
PE20130399A1 (es) 2013-04-06
EA201200098A1 (ru) 2012-07-30
BR112012000413A2 (pt) 2020-08-11
BR112012000413B1 (pt) 2022-02-15
CN102471341A (zh) 2012-05-23
US20160108051A1 (en) 2016-04-21
SI2451814T1 (sl) 2014-08-29
AU2010271247B2 (en) 2013-07-18
WO2011006143A2 (en) 2011-01-13
PT2451814E (pt) 2014-07-16
EP2737927A1 (en) 2014-06-04
CU20120002A7 (es) 2012-06-21
HK1164304A1 (en) 2012-09-21
CA2767664A1 (en) 2011-01-13
US8557801B2 (en) 2013-10-15
US20130281403A1 (en) 2013-10-24
US9469645B2 (en) 2016-10-18
JP2012532890A (ja) 2012-12-20
ES2574529T3 (es) 2016-06-20
WO2011006143A3 (en) 2011-06-09
TWI421252B (zh) 2014-01-01
UY32776A (es) 2011-02-28
JO3156B1 (ar) 2017-09-20
MY157238A (en) 2016-05-13
MX2012000389A (es) 2012-03-07
DK2451814T3 (da) 2014-07-14

Similar Documents

Publication Publication Date Title
CL2012000042A1 (es) Compuestos derivados de imidazo[1,2-a]pirazin-7-il; composición farmacéutica que comprende a uno de los compuestos; y uso de uno de los compuestos en la preparación de un medicamento útil para tratar una enfermedad relacionada con el género plasmodium en un sujeto.
CU20110216A7 (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
EA201590453A1 (ru) Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b
BR112013007696A2 (pt) composto, composição farmacêutica, usos do referido composto e da referida composição
DOP2014000303A (es) 7H-PIRROLO[2,3-d] PIRIMIDINAS 4-(AMINO-SUBSTITUIDAS) NOVEDOSAS COMO INHIBIDORES DE LRRK2
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
GEP20156417B (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
ECSP11011560A (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
UY29469A1 (es) Compuestos sulfoximino-macrocíclicos y sus sales, composiciones farmacéuticas que comprenden dichos compuestos, métodos de preparación y usos de los mismos.
UY29301A1 (es) Derivados amida
UY31730A (es) Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridinas, su preparación y su aplicación en terapéutica.
EA201490807A1 (ru) Новые замещенные имидазопиримидины как модуляторы рецептора gpbar1
CR20120237A (es) Derivados del ácido carbamoil-metil-amino-acético sustituido como inhibidores de nep novedosos
MY180666A (en) Substituted pyrazolo [3,4-b] pyridines as medicaments
UY28578A1 (es) Derivados de amida
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
ECSP14013217A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk.
AR085039A1 (es) DERIVADOS DE PURINA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA PREPARACION DE MEDICAMENTOS PARA TRATAR ENFERMEDADES MODULADAS POR LA INHIBICION DE LA PI3K DE CLASE I Y/O mTOR
UY30438A1 (es) Derivados n-sustituidos de 5-halo-4-[2-alquil-1-sustituidos-1h-imidazol-5-il]pirimidin-2-amina, composiciones-procesos para su preparacion y usos
EA201491329A1 (ru) 4,4-дизамещенные 1,4-дигидропиримидины и их применение в качестве лекарственных препаратов для лечения гепатита b
DOP2009000254A (es) Derivados de piridina
UY33731A (es) ?derivados de ácido amino-fenil-pentanoico sustituidos como inhibidores de nep?
UY30411A1 (es) Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
ECSP067111A (es) Derivados de pirido-pirimidina, su preparación, su aplicación en terapéutica